77 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
three unique therapeutic products to:
1/ slow or reverse the progression of chronic kidney disease in patients at risk of end stage kidney failure … entities designed to provide unique solutions for acute and chronic disease. Our therapeutic platforms can be used alone, or in combination, with synergistic
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
, kidney disease or diabetes that may affect the progression of acute, intermittent or chronic kidney disease.
Our commercial opportunities could … 31, 2023.
On January 3, 2024, the Company announced submission of a new patent for the treatment of chronic kidney disease (“CKD”). The patent
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
of chronic kidney disease in patients at risk of end stage kidney failure;
2/ address the immediate need of individuals facing AKI associated … . These are a complementary suite of therapeutic formulations and new chemical entities designed to provide unique solutions for acute and chronic disease. Our
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
is on developing three unique therapeutic products to:
1/ slow or reverse the progression of chronic kidney disease in patients at risk of end stage kidney failure … entities designed to provide unique solutions for acute and chronic disease. Our therapeutic platforms can be used alone, or in combination
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:11pm
, kidney disease or diabetes that may affect the progression of acute, intermittent or chronic kidney disease.
Our commercial opportunities could … 31, 2023.
On January 3, 2024, the Company announced submission of a new patent for the treatment of chronic kidney disease (“CKD”). The patent
424B3
82jkdaunkhb
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.2
aarnspj3qbhcdunrg
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-99.1
ukq9cwqc7wx jog41w0o
22 Apr 24
XORTX Announces Publication of Key Research in ADPKD
7:00am
6-K
EX-99.1
h8s85 n961cf
3 Jan 24
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
7:25am
6-K
EX-99.1
xil098
2 Jan 24
XORTX Welcomes New Member to the Board of Directors
8:12am
424B5
z40ys1
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.2
11x7 zu13
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
6-K
EX-99.1
4xk239q
2 Nov 23
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2023
7:00am
6-K
EX-99.1
ldxf9v7 2rcqvbu
28 Sep 23
XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2023
7:56am
6-K
EX-99.1
4fywyw12
7 Sep 23
XORTX Joins the Kidney Foundation and Kidney March
8:23am
6-K
EX-99.1
u0igc09rks
29 Aug 23
XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease
7:00am
424B3
1c5291ivsfr5nw7ehhn
25 Aug 23
Prospectus supplement
6:00am
424B3
3230q5fugn3az
25 Aug 23
Prospectus supplement
6:00am